Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia

This article was originally published in The Pink Sheet Daily

Executive Summary

Theravance has received two complete response letters but says it does not plan to do additional clinical studies for the new indication; Vibativ production has been halted in the U.S. and its marketing authorization withdrawn in Europe.


Related Content

Theravance Re-Introduces Vibativ In The U.S. Independently (For Now)
Theravance’s Vibativ Adds Long-Sought Pneumonia Indication
Deals Of The Week: Exit From Ambit Tie-Up Just A Blip In Astellas’ Oncology Aspirations
Theravance’s Persistence On Telavancin Rewarded With Positive Cmte. Vote
FDA Panel Breathes New Life Into Telavancin For Nosocomial Pneumonia
Mortality Vs. Clinical Cure: Telavancin Review Expected To Renew Debate On Nosocomial Pneumonia Endpoints
Theravance Faces Prospect Of Another Trial For Vibativ In Hospital-Acquired Pneumonia
No Shocker Here: Theravance Gets FDA "Complete Response" For Telavancin
Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts